EUVIMEDEUVIMED entdecken
Übersichtsarbeit

GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review

Xuejia Wang, Guangzhen Lu, Yingxue Zhou, Gang Zhao

Journal of Endocrinological Investigation · 22.05.2026 · 49 (9) · 2167-2189

DOI: 10.1007/s40618-026-02891-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 22.05.2026. Verfasst von Xuejia Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Fatty Liver, Metabolic Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 175 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide and may progress to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma, yet effective pharmacological therapies remain limited. This review summarizes current evidence on the therapeutic potential and mechanistic basis of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in MASLD. METHODS: We synthesize findings from preclinical models and clinical studies evaluating GLP-1RAs in MASLD/MASH, with emphasis on hepatic metabolic pathways, inflammatory and fibrogenic signaling, and gut-liver axis mechanisms, as well as outcomes from clinical trials and emerging multi-agonist strategies. RESULTS: Clinical studies support the therapeutic relevance of GLP-1RAs in MASLD/MASH by demonstrating reductions in liver fat content, improvements in liver enzyme profiles, and favorable histologic changes, particularly with semaglutide and emerging multi-agonist therapies in selected populations. Preclinical and translational studies further suggest that these benefits may be mediated through integrated effects on hepatic lipid handling, oxidative and inflammatory stress, fibrogenic signaling, and the gut-liver axis, although the relative contribution of direct hepatic versus indirect systemic mechanisms remains incompletely resolved. CONCLUSIONS: Current evidence supports an expanding role for GLP-1-based therapies in metabolic liver disease and provides a mechanistic framework for their continued development and clinical evaluation in MASLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsFatty LiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseHumansAnimalsSemaglutideGlucagon-Like Peptide-1 ReceptorTranslational Research, BiomedicalLiver

Stichwörter der Autor:innen

FibrosisGLP-1 receptor agonistsGut-liver axisMASHMASLD

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Shandong First Medical University, Jinan, China.
  • Department of Cardiology, Shandong Provincial Hospital Affiliated With Shandong First Medical University, Jinan, China.
  • Department of Cardiology, Shandong Provincial Hospital Affiliated With Shandong First Medical University, Jinan, China. zg000507@163.com.
  • Jinan Key Laboratory of Cardiovascular Diseases, Jinan, China. zg000507@163.com.

Förderung

  • Natural Science Foundation of Shandong Province
  • Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China

Zitieren

APA

Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026). GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review. Journal of Endocrinological Investigation, 49(9), 2167-2189. https://doi.org/10.1007/s40618-026-02891-7

Vancouver

Wang X, Lu G, Zhou Y, Zhao G. GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review. Journal of Endocrinological Investigation. 2026;49(9):2167-2189. doi:10.1007/s40618-026-02891-7

BibTeX
@article{Wang2026,
  author = {Wang, Xuejia and Lu, Guangzhen and Zhou, Yingxue and Zhao, Gang},
  title = {GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review},
  journal = {Journal of Endocrinological Investigation},
  year = {2026},
  volume = {49},
  number = {9},
  pages = {2167--2189},
  doi = {10.1007/s40618-026-02891-7}
}
Kostenlos starten →